GSK's cancer pill Tyverb falls short at NICE

GlaxoSmithKline's (NYSE: GSK) bargaining on Tyverb has failed. The U.K.'s cost-effectiveness watchdog nixed the breast-cancer pill once again--despite the company's offer to pay for the first three months of treatment.

The National Institute for Health and Clinical Excellence said the drug wasn't a good value when compared with treatment alternatives. "[E]vidence suggest that it extends life by a small amount of time--around 10 weeks or 2.4 months--and costs thousands of pounds more than one of the more commonly used NHS treatments for this indication," NICE chief Andrew Dillon said in a statement (as quoted by Dow Jones). 

NICE has been fairly skeptical of pricey cancer treatments, and, in spite of new "end-of-life" calculations for drugs for terminal illnesses, remains difficult--but not impossible--to convince. In recent weeks it has rejected one kidney cancer treatment--Bayer's Nexavar--while accepting AstraZeneca's lung cancer pill Iressa.

- check out GSK's reaction
- read the Dow Jones story
- get more from Reuters

Suggested Articles

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.

During David Loew's tenure, Sanofi Pasteur bought Protein Sciences, whose recombinant technology is being applied to a COVID-19 vaccine.